Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

(2011) T. E. Witzig et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

(2009) A. G. Ramsay et al.   BLOOD

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

(2009) Heidi Nyman et al.   MODERN PATHOLOGY

Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation

(2008) Luciano J. Costa et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lenalidomide: a novel anticancer drug with multiple modalities

(2008) Christine Galustian et al.   EXPERT OPINION ON PHARMACOTHERAPY

Lenalidomide for the Treatment of B-Cell Malignancies

(2008) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE